An exciting area of development when it comes to CLL treatment is CAR-T cells – or chimeric antigen receptor T-cells. Dr. Matthew Davids, the Associate Director of the Center for CLL at Dana-Farber Cancer Institute, says this treatment has not yet been approved by the FDA, but has shown some pretty dramatic results during research trials.
CAR-T therapy involves removing T-cells from the body and training them to recognize cancer cells in a laboratory. This is done by genetically modifying the cells, and then growing them in large numbers. When infused back into the body, these new cells seek out and destroy the CLL cells. The company that makes the drug has this list of centers that are testing it.
CAR-T therapy is showing really promising results in current clinical trials. It involves genetically modifying your own cells so they can attack cancer.
For patients diagnosed with CLL, the go-to treatment option is usually some form of chemo-immunotherapy. But this is not an option for all patients.
Oral Medicine for Relapsed CLL: Venetoclax
Oral Medicine for CLL: Ibrutinib
Oral Medicine for Relapsed CLL